New Scientist Magazine Selects ACT's Induced Pluripotent Stem (iPS) Cell-Derived
Human Platelet Program As One of '10 Ideas That Will Shape The Year'
'Revolutionary Human Stem Cell Trial' Featured as Part of '2013 Smart Guide'
MARLBOROUGH, Mass., Dec 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology,
Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative
medicine, today announced that its iPS cell-derived human platelet program has
been named as one of the "10 Ideas That Will Shape The Year" in the 'Christmas
and New Year Special' issue of the New Scientist, widely considered to be one of
the most influential science and technology news magazines in the world.
The list includes innovations in different scientific areas such as health and
medicine, climate change, technology and others. ACT's platelet program aims to
provide a renewable, donorless source of blood platelets to people in need of
platelet transfusions.
"Human iPS cells are a game-changer in medicine," said Robert Lanza, M.D., chief
scientific officer of ACT. "They offer the possibility to generate a
non-controversial, unlimited source of patient-specific stem cells without embryo
destruction. Owing to their short storage time, there is a constant demand for
this life-saving blood component. Since platelets don't contain any genetic
material, they cannot form tumors, which makes them ideal for the first clinical
trial involving the iPS cell technology. We hope to initiate the first clinical
trial using these promising cells in 2013."
ACT plans to compare normal and iPS cell-derived platelets in eight healthy
volunteers and analyze recovery and survival. Additionally, normal platelets will
be compared to human embryonic stem cell-derived platelet cells.
"We appreciate this recognition from the New Scientist," commended Gary Rabin,
chairman and CEO. "It speaks to the growing importance of the stem cell and
regenerative medicine sector."
Link to Article in New Scientist:
newscientist.com
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results,
future growth in research and development programs, potential applications of our
technology, opportunities for the company and any other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not statements
of historical fact (including statements containing the words "will," "believes,"
"plans," "anticipates," "expects," "estimates," and similar expressions) should
also be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ materially
from those indicated by such forward-looking statements, including: limited
operating history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of our intellectual property,
and economic conditions generally. Additional information on potential factors
that could affect our results and other risks and uncertainties are detailed from
time to time in the company's periodic reports, including the report on Form 10-K
for the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company's management at the time they
are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the beliefs,
opinions, and expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Company's clinical trials will
be successful.
SOURCE: Advanced Cell Technology, Inc.
Investors:
CEOcast, Inc.,
James Young, 212-732-4300
Press:
ACT Corporate Communications,
Bill Douglass, 646-450-3615
or:
Russo Partners,
Martina Schwarzkopf, Ph.D., 212-845-4292 |
